Felbamate

非尔氨酯

Report date: 2022/09/08 17:54:41
NME

Base Information

Drug NameFelbamate
Drug Alias Name非吧吗特felbamatum非氨酯felbamato非氨脂 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsBipolar DisorderSeizuresEpilepsy
Global Approved IndicationsSeizuresEpilepsy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1993/07/29
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesMeda Ab
China Registration ClassN/A

Develop Information

Active CompaniesMylan Speciality Lp
Inactive CompaniesNational Institute Of Mental Health (Nimh)Joinn Laboratories (China) Co Ltd
Active IndicationsSeizuresEpilepsy
Inactive IndicationsBipolar Disorder

Other Information

ATC CodeN03AX10
Related LinksWikipediaDrugBankKEGG